Eintrag weiter verarbeiten
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Gespeichert in:
| Zeitschriftentitel: | Hepatology |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Hepatology, 69, 2019, 5, S. 2258-2270 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. |
|---|---|
| author |
Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. |
| spellingShingle |
Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. Hepatology Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Hepatology |
| author_sort |
flynn, michael j. |
| spelling |
Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. 0270-9139 1527-3350 Ovid Technologies (Wolters Kluwer Health) Hepatology http://dx.doi.org/10.1002/hep.30337 <jats:p>After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication. The development of ICPI is particularly challenging in patients with HCC, a population with unique features which impact on safety and efficacy of immune‐modulating therapies. In this review, we discuss the biological foundations supporting the development of ICPIs across the advancing stages of HCC, focusing on the rational positioning of ICPIs across the various Barcelona‐Clinic Liver Cancer (BCLC) stages of the disease. Translational studies should guide adequate prioritization of those therapeutic agents and combination strategies which are most likely to achieve patient benefit based on solid mechanistic and clinical justifications.</jats:p> Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Hepatology |
| doi_str_mv |
10.1002/hep.30337 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXAuMzAzMzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXAuMzAzMzc |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| issn |
0270-9139 1527-3350 |
| issn_str_mv |
0270-9139 1527-3350 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
flynn2019challengesandopportunitiesintheclinicaldevelopmentofimmunecheckpointinhibitorsforhepatocellularcarcinoma |
| publishDateSort |
2019 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Hepatology |
| source_id |
49 |
| title |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_unstemmed |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_full |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_fullStr |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_full_unstemmed |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_short |
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_sort |
challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma |
| topic |
Hepatology |
| url |
http://dx.doi.org/10.1002/hep.30337 |
| publishDate |
2019 |
| physical |
2258-2270 |
| description |
<jats:p>After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication. The development of ICPI is particularly challenging in patients with HCC, a population with unique features which impact on safety and efficacy of immune‐modulating therapies. In this review, we discuss the biological foundations supporting the development of ICPIs across the advancing stages of HCC, focusing on the rational positioning of ICPIs across the various Barcelona‐Clinic Liver Cancer (BCLC) stages of the disease. Translational studies should guide adequate prioritization of those therapeutic agents and combination strategies which are most likely to achieve patient benefit based on solid mechanistic and clinical justifications.</jats:p> |
| container_issue |
5 |
| container_start_page |
2258 |
| container_title |
Hepatology |
| container_volume |
69 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346773950300167 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:43:52.575Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Challenges+and+Opportunities+in+the+Clinical+Development+of+Immune+Checkpoint+Inhibitors+for+Hepatocellular+Carcinoma&rft.date=2019-05-01&genre=article&issn=1527-3350&volume=69&issue=5&spage=2258&epage=2270&pages=2258-2270&jtitle=Hepatology&atitle=Challenges+and+Opportunities+in+the+Clinical+Development+of+Immune+Checkpoint+Inhibitors+for+Hepatocellular+Carcinoma&aulast=Pinato&aufirst=David+J.&rft_id=info%3Adoi%2F10.1002%2Fhep.30337&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346773950300167 |
| author | Flynn, Michael J., Sayed, Anwar A., Sharma, Rohini, Siddique, Abdul, Pinato, David J. |
| author_facet | Flynn, Michael J., Sayed, Anwar A., Sharma, Rohini, Siddique, Abdul, Pinato, David J., Flynn, Michael J., Sayed, Anwar A., Sharma, Rohini, Siddique, Abdul, Pinato, David J. |
| author_sort | flynn, michael j. |
| container_issue | 5 |
| container_start_page | 2258 |
| container_title | Hepatology |
| container_volume | 69 |
| description | <jats:p>After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication. The development of ICPI is particularly challenging in patients with HCC, a population with unique features which impact on safety and efficacy of immune‐modulating therapies. In this review, we discuss the biological foundations supporting the development of ICPIs across the advancing stages of HCC, focusing on the rational positioning of ICPIs across the various Barcelona‐Clinic Liver Cancer (BCLC) stages of the disease. Translational studies should guide adequate prioritization of those therapeutic agents and combination strategies which are most likely to achieve patient benefit based on solid mechanistic and clinical justifications.</jats:p> |
| doi_str_mv | 10.1002/hep.30337 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXAuMzAzMzc |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0270-9139, 1527-3350 |
| issn_str_mv | 0270-9139, 1527-3350 |
| language | English |
| last_indexed | 2024-03-01T17:43:52.575Z |
| match_str | flynn2019challengesandopportunitiesintheclinicaldevelopmentofimmunecheckpointinhibitorsforhepatocellularcarcinoma |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 2258-2270 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Hepatology |
| source_id | 49 |
| spelling | Flynn, Michael J. Sayed, Anwar A. Sharma, Rohini Siddique, Abdul Pinato, David J. 0270-9139 1527-3350 Ovid Technologies (Wolters Kluwer Health) Hepatology http://dx.doi.org/10.1002/hep.30337 <jats:p>After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication. The development of ICPI is particularly challenging in patients with HCC, a population with unique features which impact on safety and efficacy of immune‐modulating therapies. In this review, we discuss the biological foundations supporting the development of ICPIs across the advancing stages of HCC, focusing on the rational positioning of ICPIs across the various Barcelona‐Clinic Liver Cancer (BCLC) stages of the disease. Translational studies should guide adequate prioritization of those therapeutic agents and combination strategies which are most likely to achieve patient benefit based on solid mechanistic and clinical justifications.</jats:p> Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Hepatology |
| spellingShingle | Flynn, Michael J., Sayed, Anwar A., Sharma, Rohini, Siddique, Abdul, Pinato, David J., Hepatology, Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma, Hepatology |
| title | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_full | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_fullStr | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_full_unstemmed | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_short | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| title_sort | challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma |
| title_unstemmed | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma |
| topic | Hepatology |
| url | http://dx.doi.org/10.1002/hep.30337 |